Colchicine revisited

Research output: Chapter in Book/Report/Conference proceedingConference contribution

46 Citations (Scopus)

Abstract

Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages766-773
Number of pages8
Volume1173
DOIs
StatePublished - Sep 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Colchicine
Linear IgA Bullous Dermatosis
Relapsing Polychondritis
Sweet Syndrome
Epidermolysis Bullosa
Aphthous Stomatitis
Familial Mediterranean Fever
Dermatomyositis
Biliary Liver Cirrhosis
Gout
Kidney Diseases
Amyloidosis
Psoriasis
Pharmaceutical Preparations
Biological Availability
Liver Diseases
Liver
Immunoglobulin A
Toxicity
Erythema elevatum diutinum

Keywords

  • Arthritis
  • Gout
  • Uric acid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bhat, A., Naguwa, S. M., Cheema, G. S., & Gershwin, M. E. (2009). Colchicine revisited. In Annals of the New York Academy of Sciences (Vol. 1173, pp. 766-773). (Annals of the New York Academy of Sciences; Vol. 1173). https://doi.org/10.1111/j.1749-6632.2009.04674.x

Colchicine revisited. / Bhat, Anupama; Naguwa, Stanley M; Cheema, Gurtej S.; Gershwin, M. Eric.

Annals of the New York Academy of Sciences. Vol. 1173 2009. p. 766-773 (Annals of the New York Academy of Sciences; Vol. 1173).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bhat, A, Naguwa, SM, Cheema, GS & Gershwin, ME 2009, Colchicine revisited. in Annals of the New York Academy of Sciences. vol. 1173, Annals of the New York Academy of Sciences, vol. 1173, pp. 766-773. https://doi.org/10.1111/j.1749-6632.2009.04674.x
Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. In Annals of the New York Academy of Sciences. Vol. 1173. 2009. p. 766-773. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.04674.x
Bhat, Anupama ; Naguwa, Stanley M ; Cheema, Gurtej S. ; Gershwin, M. Eric. / Colchicine revisited. Annals of the New York Academy of Sciences. Vol. 1173 2009. pp. 766-773 (Annals of the New York Academy of Sciences).
@inproceedings{7c5250e483084c13a4054f17cec201f0,
title = "Colchicine revisited",
abstract = "Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Beh{\cc}et's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.",
keywords = "Arthritis, Gout, Uric acid",
author = "Anupama Bhat and Naguwa, {Stanley M} and Cheema, {Gurtej S.} and Gershwin, {M. Eric}",
year = "2009",
month = "9",
doi = "10.1111/j.1749-6632.2009.04674.x",
language = "English (US)",
isbn = "9781573317627",
volume = "1173",
series = "Annals of the New York Academy of Sciences",
pages = "766--773",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Colchicine revisited

AU - Bhat, Anupama

AU - Naguwa, Stanley M

AU - Cheema, Gurtej S.

AU - Gershwin, M. Eric

PY - 2009/9

Y1 - 2009/9

N2 - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

AB - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

KW - Arthritis

KW - Gout

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=69949135704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949135704&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04674.x

DO - 10.1111/j.1749-6632.2009.04674.x

M3 - Conference contribution

C2 - 19758227

AN - SCOPUS:69949135704

SN - 9781573317627

VL - 1173

T3 - Annals of the New York Academy of Sciences

SP - 766

EP - 773

BT - Annals of the New York Academy of Sciences

ER -